By demonstrating the comparable efficacy between lower dose erlotinib and standard dose gefitinib in EGFR-mutated NSCLC, our results could facilitate the development of EGFR TKI-based combination therapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.